Literature DB >> 17562623

Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.

Masao Nakagawa1, Satoshi Hashino, Mutsumi Takahata, Takahito Kawamura, Fumie Fujisawa, Kaoru Kahata, Takeshi Kondo, Masahiro Imamura, Sachiko Ando, Masahiro Asaka.   

Abstract

A 56-year-old woman with a poor-prognosis chronic active Epstein-Barr virus (CAEBV) infection underwent reduced-intensity stem cell transplantation (RIST) using cryopreserved cord blood (CB). Administration of EBV-seronegative CB cells following a reduced-intensity conditioning regimen was effective and well tolerated. Complete remission with no symptoms, low titers of EBV-related antibodies, and an undetectable level of EBV DNA in peripheral blood mononuclear cells continued for 16 months after RIST. This report is the first of successful RIST with CB for an adult with CAEBV infection. The results also show that a graft-versus-CAEBV effect can be achieved in an allogeneic hematopoietic stem cell transplantation setting.

Entities:  

Mesh：

Year:  2007        PMID： 17562623     DOI： 10.1532/IJH97.06115

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  10 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.

Authors:  Keisei Kawa; Takayuki Okamura; Masahiro Yasui; Emiko Sato; Masami Inoue
Journal:  Crit Rev Oncol Hematol       Date:  2002-12       Impact factor: 6.312

Review 2.  The chronic mononucleosis syndrome.

Authors:  S E Straus
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

Review 3.  Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection.

Authors:  Motohiko Okano; Keisei Kawa; Hiroshi Kimura; Akihiro Yachie; Hiroshi Wakiguchi; Akihiko Maeda; Shosuke Imai; Shouichi Ohga; Hirokazu Kanegane; Shigeru Tsuchiya; Tomohiro Morio; Masaaki Mori; Shumpei Yokota; Shinsaku Imashuku
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

4.  Successful umbilical cord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation.

Authors:  Masataka Ishimura; Shouichi Ohga; Akihiko Nomura; Taikai Toubo; Eiji Morihana; Yusuke Saito; Hisanori Nishio; Makoto Ide; Hidetoshi Takada; Toshiro Hara
Journal:  Am J Hematol       Date:  2005-11       Impact factor: 10.047

5.  Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.

Authors:  I Tsuge; T Morishima; H Kimura; K Kuzushima; H Matsuoka
Journal:  J Med Virol       Date:  2001-06       Impact factor: 2.327

6.  Prognostic factors for chronic active Epstein-Barr virus infection.

Authors:  Hiroshi Kimura; Tsuneo Morishima; Hirokazu Kanegane; Shouichi Ohga; Yo Hoshino; Akihiko Maeda; Shosuke Imai; Motohiko Okano; Tomohiro Morio; Shumpei Yokota; Shigeru Tsuchiya; Akihiro Yachie; Shinsaku Imashuku; Keisei Kawa; Hiroshi Wakiguchi
Journal:  J Infect Dis       Date:  2003-01-28       Impact factor: 5.226

7.  [Chronic active Epstein-Barr virus infection treated with reduced intensity stem cell transplantation].

Authors:  Naoki Sakata; Emiko Sato; Akihisa Sawada; Masahiro Yasui; Masami Inoue; Keisei Kawa
Journal:  Rinsho Ketsueki       Date:  2004-05

8.  Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.

Authors:  H Kimura; I Tsuge; S Imai; M Yamamoto; K Kuzushima; T Osato; T Morishima
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402

9.  Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection.

Authors:  Taeko Uehara; Chiaki Nakaseko; Satoru Hara; Akane Harima; Megumi Ejiri; Akira Yokota; Yasushi Saito; Miki Nishimura
Journal:  Am J Hematol       Date:  2004-08       Impact factor: 10.047

10.  Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting.

Authors:  F Yoshiba; M Hagihara; K Tazume; Y Ogawa; K Kishi; A Higuchi; S Kato; T Hotta
Journal:  Bone Marrow Transplant       Date:  2003-07       Impact factor: 5.483
  10 in total
  4 in total

1.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

2.  Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.

Authors:  Yasushi Onishi; Koichi Onodera; Noriko Fukuhara; Hiroki Kato; Satoshi Ichikawa; Tohru Fujiwara; Hisayuki Yokoyama; Minami Yamada-Fujiwara; Hideo Harigae
Journal:  Int J Hematol       Date:  2022-03-10       Impact factor: 2.490

3.  Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection.

Authors:  Masuho Saburi; Masao Ogata; Takako Satou; Natsumi Yoshida; Kentaro Nagamatsu; Yuko Nashimoto; Yui Moroga; Kuniko Takano; Kazuhiro Kohno; Kuniaki Shirao
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

4.  Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion.

Authors:  Michihide Tokuhira; Atsushi Iizuka; Reiko Watanabe; Naoya Sekiguchi; Norihide Sato; Chen-Kang Chien; Yasunobu Sekiguchi; Tomoe Nemoto; Kyoko Hanzawa; Jun-Ichi Tamaru; Shinji Itoyama; Hiroshi Suzuki; Tsutomu Takeuchi; Shigehisa Mori; Masahiro Kizaki
Journal:  Int J Hematol       Date:  2008-04-23       Impact factor: 2.319
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.